Drug intelligence / Profile preview

Metbest XL 25

Development stage: Unknown
Lead developer: Astra Care Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Metbest XL 25 is a branded generic formulation of metoprolol succinate, an extended-release selective beta-1 adrenergic receptor blocker. Developed and distributed by Astra Care Pharmaceuticals, it is primarily used to treat cardiovascular conditions including hypertension, angina pectoris, and cardiac arrhythmias, as well as for the secondary prevention of myocardial infarction and the prophylaxis of migraine. By selectively antagonizing beta-1 receptors in the heart, it reduces heart rate, cardiac output, and blood pressure, thereby decreasing the heart's workload and oxygen demand.

Brand names: Metbest XL 25Metbest-XL 25 TabletMetbest-XL25 TabletMetbest-XL-25 Tablet
Other names: Metbest-XL 25Metbest-XL25Metbest-XL-25

Targets

ADRB1 (β1)ADRB2 (β2)

Beyond the preview

Go deeper on Metbest XL 25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metbest XL 25.

Explore the full profile